SENATE . No. 00548

The Commonwealth of Massachusetts

PRESENTED BY:

Michael J. Rodrigues

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the passage of the accompanying bill:

An Act relative to manufacturer rebates and discount programs.

 \Box .

PETITION OF:

NAME:	DISTRICT/ADDRESS:
Michael J. Rodrigues	First Bristol and Plymouth
Karen E. Spilka	Second Middlesex and Norfolk
Benjamin B. Downing	Berkshire, Hampshire, and Franklin
Michael O. Moore	Second Worcester
James E. Timilty	Bristol and Norfolk
Michael R. Knapik	Second Hampden and Hampshire
Sal N. DiDomenico	Middlesex, Suffolk, and Essex
Barry R. Finegold	Second Essex and Middlesex
Michael F. Rush	Suffolk and Norfolk
Katherine M. Clark	Middlesex and Essex
James T. Welch	Hampden
Robert L. Hedlund	Plymouth and Norfolk
John F. Keenan	Norfolk and Plymouth
Jay Kaufman	15th Middlesex
David B. Sullivan	6th Bristol
Stephen R. Canessa	12th Bristol

Linda Dorcena Forry	12th Suffolk
John W. Scibak	2nd Hampshire
Cory Atkins	14th Middlesex
Sarah K. Peake	4th Barnstable
Martha M. Walz	8th Suffolk
F. Jay Barrows	1st Bristol
Kevin Aguiar	7th Bristol
Paul Schmid, III	8th Bristol

SENATE No. 00548

By Mr. Rodrigues, petition (accompanied by bill, Senate, No. 548) of Schmid, Aguiar, Barrows and other members of the General Court for legislation relative to manufacturer rebates and discount programs [Joint Committee on Health Care Financing].

[SIMILAR MATTER FILED IN PREVIOUS SESSION SEE

□ HOUSE , NO. *4689* OF 2009-2010.]

The Commonwealth of Massachusetts

In the Year Two Thousand Eleven

An Act relative to manufacturer rebates and discount programs.

 \Box .

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

- SECTION 1. Section 3 of chapter 175H of the General Laws, as appearing in the 2008
- 2 Official Edition, is hereby amended by inserting before the word "Any", in line 1, the following:-
- 3 (a).
- 4 SECTION 2. Said section 3 of said chapter 175H, as so appearing, is hereby further
- 5 amended by inserting after word "rebate", in line 7, the following words:- except as provided in
- 6 subsection (b),.
- 7 SECTION 3. Said section 3 of said chapter 175H, as so appearing, is hereby further
- 8 amended by adding the following 3 subsections:-

- 9 (b) This section shall not apply to a discount, rebate, product voucher or other reduction in an individual's out-of-pocket expenses, including co-payments and deductibles on a prescription drug, biologic or vaccine provided by a pharmaceutical manufacturing company, as 11 defined in section 1 of chapter 111N, that is made available to an individual if the discount, 12 rebate, product voucher or other reduction is provided directly or electronically to the individual 13 14 or through a point of sale or mail-in rebate, or through similar means; provided, however, that a pharmaceutical manufacturing company shall not exclude nor favor any pharmacy in the 15 redemption of such discount, rebate, product voucher or other expense reduction offer to an 16 17 individual.
- (c) This subsection shall not: (i) restrict a pharmaceutical manufacturing company with regard to how it distributes a prescription drug, biologic or vaccine; or (ii) restrict a carrier or a health maintenance organization, as defined in section 1 of chapter 118G, with regard to how its plan design will treat such discounts, rebates, product voucher or other reduction in out-of-pocket expenses.
- 23 (d) For purposes of the federal Health Insurance Portability and Accountability Act of 24 1996, hereinafter HIPAA, and regulations promulgated under HIPAA, nothing in this subsection 25 shall be deemed to require or allow the use or disclosure of health information in any manner 26 that does not otherwise comply with HIPAA or regulations promulgated under HIPAA.
- SECTION 4. The division of health care finance and policy, in consultation with the
 department of public health shall conduct an analysis of the impact on health care costs of the
 use of discounts, rebate, product voucher or other reduction for prescription drugs. The report
 shall include, but not be limited to, an analysis of the impact on commercial health insurance

- 31 premiums and on premiums associated with the group insurance commission, and a comparison
- 32 of any change in utilization of generic versus brand name prescription drugs. The division shall
- file a report of its findings with the clerks of the senate and house of representatives, the house
- 34 and senate committees on ways and means and the joint committee on health care financing by
- not later than March 15, 2013.